Latest Share Chat

REMOVE ADS

Astrazeneca Share News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes

Get Live Data

13,290.00 56.00 (0.42%)

Bid:

13,338.00

Ask:

13,344.00

Spread: 6.00 (0.045%)

Market Cap: £206.11b

Last checked at -

Intraday Astrazeneca Share Chart

REMOVE ADS

Astrazeneca News

AstraZeneca hails Imfinzi and Imjudo liver cancer trial results

(Alliance News) - AstraZeneca PLC on Monday posted positive phase-three trial results for a combination of its drugs Imfinzi and Imjudo to treat a for...

Market Reports

EARNINGS: Polar Capital Global Healthcare lags benchmark index

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News:

Funds

AstraZeneca highlights data insights from Cares clinical programme

(Alliance News) - AstraZeneca PLC on Friday announced that the CARES phase 3 clinical programme did not meet a primary endpoint, but noted insightful ...

Market Reports

WINNERS & LOSERS: CelLBxHealth jumps on AstraZeneca partnership

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday.

Risers and Fallers

CelLBxHealth shares jump on partnership with AstraZeneca

(Alliance News) - CelLBxHealth PLC on Friday disclosed that it has entered a partnership with AstraZeneca PLC.

Corporate News

LONDON MARKET OPEN: FTSE 100 climbs as US-Iran deal draws closer

(Alliance News) - Stock prices in London opened higher on Friday, amid renewed hope for a deal between the US and Iran, which is reportedly awaiting t...

Market News

LONDON BRIEFING: Ocado teams with Asda; AstraZeneca drug gets US nod

(Alliance News) - Ocado Group strikes a deal with UK supermarket Asda, an AstraZeneca drug wins US approval to treat bladder cancer and Serabi Gold's ...

Corporate News

Astrazeneca's Imfinzi receives green light from US FDA

(Sharecast News) - Drugmaker Astrazeneca said on Friday that Imfinzi has been approved in the US as part of the first immunotherapy‑based combin...